Sangamo Therapeutics Inc. ( SGMO ) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. ( PFE ) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring "all options" to continue the program.

Morning Brief co-hosts Madison Mills and Seana Smith break down the details.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here .

This post was written by Angel Smith